Regeneron Pharmaceuticals (REGN) Non Operating Income (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Non Operating Income of $234.3 million for Q2 2026, down 46.65% year-over-year from $439.2 million in Q2 2025, and up 24.43% quarter-over-quarter from $188.3 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Non Operating Income (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Non Operating Income history runs 18 years deep, the most recent figure standing at $234.3 million for Q2 2026.
- In Q2 2026, Non Operating Income fell 46.65% year-over-year to $234.3 million; the TTM figure through Jun 2026 stood at $1.3 billion (up 27.95% YoY), while the FY2025 annual figure was $1.7 billion, up 109.43% from the prior year.
- Non Operating Income for Q2 2026 stood at $234.3 million, up from $188.3 million in the prior quarter.
- The five-year high for Non Operating Income was $736.5 million in Q3 2025, with the low at -$197.4 million in Q1 2022.
- The 5-year median for Non Operating Income is $176.3 million (2022), against an average of $174.3 million.
- The sharpest annual moves came in 2022 and 2024: Non Operating Income sank 240.7% in 2022, then surged 156850.0% in 2024.
- Regeneron Pharmaceuticals' Non Operating Income stood at $177.9 million in 2022, then dropped by 1.8% to $174.7 million in 2023, then tumbled by 118.37% to -$32.1 million in 2024, then jumped by 610.28% to $163.8 million in 2025, then surged by 43.04% to $234.3 million in 2026.
- Business Quant data shows REGN's Non Operating Income at $234.3 million in Q2 2026, $188.3 million in Q1 2026, and $163.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 234.30 Mn |
| Mar 31, 2026 | 188.30 Mn |
| Dec 31, 2025 | 163.80 Mn |
| Sep 30, 2025 | 736.50 Mn |
| Jun 30, 2025 | 439.20 Mn |
| Mar 31, 2025 | 313.30 Mn |
| Dec 31, 2024 | -32.10 Mn |
| Sep 30, 2024 | 313.50 Mn |
| Jun 30, 2024 | 558.50 Mn |
| Mar 31, 2024 | -50.70 Mn |
| Dec 31, 2023 | 174.70 Mn |
| Sep 30, 2023 | -200,000.00 |
| Jun 30, 2023 | 66.40 Mn |
| Mar 31, 2023 | -88.70 Mn |
| Dec 31, 2022 | 177.90 Mn |
| Sep 30, 2022 | 286.10 Mn |
| Jun 30, 2022 | -146.70 Mn |
| Mar 31, 2022 | -197.40 Mn |
| Dec 31, 2021 | -136.30 Mn |
| Sep 30, 2021 | -30.60 Mn |